Aktienanalyse zu Adlai Nortye Group Ltd (ANL)ANLAdlai Nortye Group Ltd

Adlai Nortye Group Ltd. is a clinical-stage biotechnology company. The Company is engaged in the research and development of pharmaceutical products. It is developing targeted and immune-modulating cancer therapies. Its RAS-targeting portfolio includes AN9025, an oral pan-RAS(ON) inhibitor for RAS-driven cancers, and AN4035, a CEACAM5-targeting antibody-drug conjugate (ADC) delivering a potent pan-RAS(ON) inhibitor directly to tumors. It is also developing cancer immunotherapies, including AN8025, a tri-functional fusion protein (aPD-L1 × CD86 variant × LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005, a first-in-class oral small-molecule PD-L1 inhibitor, which are designed to activate cancer immunity in novel ways. Its pipeline also includes AN0025, a small molecule EP4 antagonist designed to modulate the tumor microenvironment. It operates in the Healthcare sector.

Adlai Nortye Ltd (ANL) is a good buy right now due to its recent price performance and strong analyst ratings. The stock is currently priced at $13.82, with a year-to-date change of +901.45%, indicating significant growth potential. Analysts have set price targets ranging from $20 to $32, suggesting an upside of 45% to 132% from the current price. However, the company is facing a risk with a negative net margin of -710.56% projected for Q4 2025, which highlights the need for careful monitoring of its financial health.